What is the annual cost to provide menopause treatments in the United
States? The number needs to be from a reputable source, either
government (e.g., CDC) or industry (e.g., health plans, ACOG) and
should be within the last five years or so. The number could be all
menopause treatments or HRT (hormone replacement therapy) or office
visits to treat symptoms of menopause.

Fred,

It's me again.  I've an answer for you this time.  You'll find it at:

http://www.dresources.com/dr/Reports.nsf/BrowseAbstracts/6C5A3EE93F2C833E86256AAA006898D0?OpenDocument

where a market studies firm, Decision Resources, concludes that:
"Market outlook: The market for HRT totaled $3.2 billion in 2000." 
Although they don't give a breakdown by region on the internet (they
do in their report, for sale) they do refer to the "huge size of the
U.S. market relative to the European and Japanese markets for HRT" so
that it's clear that the American market is very dominant in global
sales thus far.


This is also a very fast growing area of medicine, as mentioned at:

http://www.bccresearch.com/editors/RB-111R.html

MARKET FOR DRUGS AND COSMETICS CONTINUE TO TAP
THE AGING BABY BOOMERS GENERATION (press release 1/24/02)

"The market with the highest projected average annual growth rate
(16.5%) driven by aging boomers is the hormone replacement therapy
market. The number of aging female boomers seeking treatment for
relief of menopausal symptoms is steadily increasing."


Hope this is what you needed, but if not, let me know. 

Search: ["hormone replacement therapy" market size]

I actually liked the free answer better, more to my needs. I also
appreciated the fast turnaround, too, although I was out celebrating
Father's Day this weekend and could not get to this until this
evening. I've spent 6-8 hours researching online to get an answer to
this question and therefore I'm grateful for the nuggets you dug up.

Hello Fred.  This might get you very close to what you're looking for,
but it didn't seem to hit the nail on the head...

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10565666&dopt=Abstract

J Womens Health Gend Based Med 1999 Oct;8(8):1077-89 Related Articles,
Books, LinkOut


Healthcare use among U.S. women aged 45 and older: total costs and
costs for selected postmenopausal health risks.

Hoerger TJ, Downs KE, Lakshmanan MC, Lindrooth RC, Plouffe L Jr,
Wendling B, West SL, Ohsfeldt RL.

Research Triangle Institute, Research Triangle Park, North Carolina
27709, USA.

The purpose of this study is to estimate the level of healthcare use
and costs incurred by postmenopausal women overall and for these
selected conditions: cardiovascular disease, osteoporosis, breast
cancer, and gynecological cancers. National healthcare survey and
discharge data were used to estimate healthcare use by women aged 45
and older. Clinical Classification for Health Policy Research (CCHPR)
codes were used to identify patients whose primary diagnosis or
procedure corresponded with the selected conditions. National weights
were used to estimate resource use. Treatment costs were estimated
using cost/charge ratios or the Medicare fee schedule to calculate
costs for each individual procedure. Estimated total annual medical
care treatment costs for women 45 and older were about $186 billion in
1997 dollars, including about $60.4 billion for cardiovascular
disease, $12.9 billion for osteoporosis, and $5.0 billion for breast
and gynecological cancers. For each condition, estimated resource use
and costs are reported for hospitalization, outpatient, nursing home,
and home healthcare services. Resource use and costs are also reported
by age and expected source of payment. The economic burden of disease
for conditions commonly affecting postmenopausal women is substantial.
Prior research establishes that hormone replacement therapy (HRT) may
be effective in reducing the burden of disease among women who
continue preventive therapy for many years, but few at-risk women do
so. New alternatives for prevention, such as selective estrogen
receptor modulators (SERMs), may be effective in reducing the burden
of disease among postmenopausal women.